导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.58% | 3372/4773 |
| 近一周 | -3.39% | 4727/5465 |
| 近一月 | -3.94% | 2918/5421 |
| 近一季 | -3.73% | 1674/5231 |
| 近半年 | -7.91% | 3430/4920 |
| 近一年 | -3.39% | 3100/4394 |
| 近两年 | 32.14% | 2202/2954 |
| 近三年 | 9.73% | 1765/2253 |
| 成立以来 | 144.01% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.53% 2347/4961 |
0.12% 3208/5312 |
- - |
- - |
| 2025 | 12.50% 2689/4813 |
-0.66% 2344/3635 |
-1.99% 3290/4076 |
16.53% 2639/4524 |
-0.84% 2683/4813 |
| 2024 | 10.76% 1379/3463 |
2.47% 772/2808 |
-3.87% 1428/3014 |
18.26% 1031/3129 |
-4.92% 2505/3463 |
| 2023 | -5.35% 729/2656 |
6.32% 698/2280 |
-4.63% 1227/2385 |
0.12% 386/2515 |
-6.77% 1913/2655 |
| 2022 | -17.38% 583/2207 |
-10.25% 384/1919 |
1.92% 1403/2016 |
-12.17% 658/2113 |
2.85% 820/2208 |
| 2021 | -2.83% 874/1822 |
0.94% 270/1255 |
-0.93% 1153/1330 |
-2.26% 560/1466 |
-0.57% 1251/1822 |
| 2020 | 23.68% 646/1250 |
-11.55% 841/1028 |
11.90% 713/1067 |
10.66% 527/1164 |
12.92% 414/1184 |
| 2019 | 46.45% 134/1092 |
34.08% 123/754 |
-2.03% 342/804 |
0.27% 538/850 |
11.20% 74/918 |
| 2018 | -25.04% 338/834 |
- - |
- - |
- - |
-9.56% 150/691 |
| 2017 | 33.16% 46/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.72% 181/605 |
- - |
- - |
- - |
- - |
| 2015 | 19.98% 117/575 |
- - |
- - |
- - |
- - |
| 2014 | 49.72% 87/237 |
- - |
- - |
- - |
- - |
| 2013 | -5.36% 96/186 |
- - |
- - |
- - |
- - |
| 2012 | 0.96% 106/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实深证基本面120联接A VS. 长安沪深300非周期A(740101) |